Date: 2014-09-09
Type of information: Construction of new premises
Compound:
Company: Probiogen (Germany)
Therapeutic area: Technology - Services
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On September 9, 2014, Probiogen announced to invest 20€ million and to double its workforce. On behalf of pharmaceutical and biotech companies ProBioGen is developing novel biotechnological processes for the production of biopharmaceutical drug substances to treat serious diseases. The service spectrum ranges from cell line and process development up to GMP contract manufacturing. In addition, the Berlin scientists develop innovative technologies to improve biotechnologically active substances and by virtue of their recognized scientific excellence created an extensive portfolio of proprietary rights for optimized biopharmaceutical manufacturing. In recent times, licenses were granted to several global pharmaceutical companies, including Boehringer Ingelheim and Novartis. Beyond that, ProBioGen will further exploit its internal potential for the development of production cell lines, process engineering and GMP manufacturing of biopharmaceuticals. Probiogen will continue to expand in Berlin. This investment of around 20 million euros will be used to strengthen Probiogen's market position and add two additional disposable 1000L bioreactors. Within the next two years, the companu will also double its staff from currently 75 highly skilled and dedicated employees.
Financial terms:
Latest news:
